Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2024; 16(12): 1429-1440
Published online Dec 27, 2024. doi: 10.4254/wjh.v16.i12.1429
Clinical profiles and their interaction of concurrent metabolic associated steatotic liver disease and hepatitis B virus infection
Shao-Wen Wang, Yu-Wen Chang, Ching Wang, Yu-Ming Cheng, Tsung-Han Hsieh, Chia-Chi Wang, Jia-Horng Kao
Shao-Wen Wang, Department of Education, Taipei Medical University-Shuang Ho Hospital, Taipei 235, Taiwan
Yu-Wen Chang, Department of Gastroenterology and Hepatology, Taipei Tzu Chi Hospital, Taipei 231, Taiwan
Ching Wang, Department of Education, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan
Yu-Ming Cheng, Department of Gastroenterology and Hepatology, Tung’s Taichung MetroHarbor Hospital, Taichung 43503, Taiwan
Tsung-Han Hsieh, Research, Taipei Tzu Chi Hospital, Taipei 231, Taiwan
Chia-Chi Wang, Department of Hepatology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan
Jia-Horng Kao, Department of Internal Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan
Co-first authors: Shao-Wen Wang and Yu-Wen Chang.
Author contributions: Wang SW and Wang C contributed to writing of the article; Cheng YM and Hsieh TH contributed to statistical analysis; Wang CC contributed to concept, design and writing of the article; Kao JH contributed to revising the article. Wang SW and Chang YW contributed the same contribution and as such merited the designation of co-first authorship.
Supported by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. TCRD-TPE-112-11.
Institutional review board statement: The authors declare the data were made available to and approved by the Ethics and Governance Council of the Taiwan Bio-bank (Approval Numbers: TWBR11102-03).
Informed consent statement: This was a retrospective study from the Taiwan Bio-bank. Therefore, this study did not require any informed consent forms.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chia-Chi Wang, PhD, Chief, Department of Hepatology, Taipei Tzu Chi Hospital, No. 289 Jianguo Road, Xindian Area, New Taipei City 23142, Taiwan. wangchiachi888@gmail.com
Received: May 23, 2024
Revised: July 23, 2024
Accepted: July 30, 2024
Published online: December 27, 2024
Processing time: 189 Days and 23.3 Hours
Core Tip

Core Tip: Patients with concurrent metabolic associated steatotic liver disease (MASLD) and hepatitis B virus (HBV) infection (MASLD-HBV) are occasionally encountered in clinical practice. They have different clinical profiles compared to MASLD or “HBV alone” patients. The patients with dual etiology have worse liver fibrosis severity than MASLD patients, but better liver fibrosis stage than “HBV alone” patients, suggesting a complex interaction between MASLD and chronic HBV infection.